EBF1 suppression is mediated via different mechanisms such as genomic loss in breast cancer 11, point mutation in pancreatic ductal adenocarcinoma 13, overexpression of EBF1 inhibitors (ZNF423 and ZNF521) in many cancers, such as CCA 14, acute lymphoblastic leukemia 15 and nasopharyngeal carcinoma 16, and aberrant expression of microRNAs targeting EBF1 in white adipose tissues 17. This evidence concerns the gene EBF1 and cholangiocarcinoma.